Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (401)	1/29/2003 2:43:12 PM
From: Czechsinthemail	Respond to of 598

Actually, we may hear some interesting things from TLRK, but it is likely to be news related to partnerships and financing deals, new IND candidates and perhaps more on the patent front (if Rick continues his searches) rather than clinical results. My guess is that they might want to find partnerships for T67 and perhaps the antibody side of the oncogene program, saving the P1 candidates for later. I would agree that the shareholders are at a disadvantage given TLRK's predilections toward stealth. If they are shopping for partnerships or financing, they will have to disclose information. This leaves shareholders the last to know. On the plus side, the stock is now priced like a LEAP, so you can play the considerable upside potential of their program at low cost.

To: keokalani'nui who wrote (401)	1/29/2003 2:52:10 PM
From: fred hayes	Respond to of 598

>So the company will need cash, soon...< At JPM conference, indicated enuf cash for 2 years. Have about $167 mil 12/31/02, and apparently potential deals cooking. Based on biotech standards, cash situation doesn't seem to be too bad. Hope I'm not being too optimistic (my usual problem)... fred hayes

To: keokalani'nui who wrote (401)	1/29/2003 4:04:10 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 598

Goeddel, running alone down the path that he couldn't sell to investors, 607/67. Sigh. Hurts. One gets burned, running into "distribution". But, if he hadn't made such a critical error, the opportunity of TLRK wouldn't be offered up at a research premium of $100M. You're ticked about communications with scientists. I'm ticked at the continuous flow of hedge fund managers who know, beforehand, about biotech "distributions" and forward sales agreements. >> That is, the company owes it to those who will stick with it through the next 18 months to keep tight lips << For some time, Goeddel has been adamant that the company had good partnership discussions, that there was only upside to be gained from patience. His shareholders who bought into this quiet confidence or not-overt arrogance? We have 100% of the paper but (arbitrary, based on my pain to date) 25% of the value.